16:51 , Apr 22, 2019 |  BioCentury  |  Finance

Poseida's sea change

Rather than execute the IPO it proposed in January, Poseida has instead raised a $142 million series C round that includes a $75 million contribution from Novartis. CEO Eric Ostertag told BioCentury that Poseida has...
23:41 , Apr 19, 2019 |  BioCentury  |  Product Development

Companies poised to take Chinese checkpoints global

At least three companies are well positioned to answer FDA Oncology chief Richard Pazdur’s call to bring Chinese PD-1/PD-L1 inhibitors to the U.S. to compete on price. Two Chinese drugmakers and one U.S. company globally...
21:34 , Apr 19, 2019 |  BC Week In Review  |  Clinical News

Eiger raises $49.5M following Phase II HDV readout for Lambda

Eiger reported data from the Phase II LIMT HDV trial showing that high-dose Lambda as monotherapy led to a 36% durable virologic response rate at 24 weeks following treatment among 14 evaluable patients with chronic...
16:25 , Apr 19, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 12 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Europe; premarket on U.S. exchange; (B) Full-year EPS for fiscal year ended March...
00:42 , Apr 19, 2019 |  BC Week In Review  |  Clinical News

BMS reports detailed survival data for failed Opdivo maintenance trial in SCLC

Bristol-Myers said Opdivo nivolumab plus Yervoy ipilimumab as maintenance therapy of extensive-stage disease small cell lung cancer following first-line platinum-based chemotherapy led to a median overall survival of 9.2 months vs. 9.6 months for placebo...
11:00 , Apr 18, 2019 |  BioCentury  |  Finance

Arranging Arrakis' syndicate

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become...
16:40 , Apr 12, 2019 |  BC Extra  |  Company News

BMS, Celgene shareholders approve acquisition

Shareholders from both BMS and Celgene voted Friday to approve the pharma's acquisition of the biotech for $74 billion in a cash and stock deal. While the deal had its share of opposition and support,...
13:59 , Apr 9, 2019 |  BC Extra  |  Company News

BeiGene, BioAtla in deal for conditionally activated CTLA-4 inhibitor

BioAtla granted BeiGene a license to BA3071 (CAB-CTLA-4), a conditionally activated inhibitor of CTLA-4, that the partners will develop jointly to treat cancer. The companies plan to test the mAb as monotherapy and in combination...
00:16 , Apr 6, 2019 |  BioCentury  |  Finance

Room to rally in 2Q

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...